Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily Mason-Osann

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|May 26, 2019
Direct Visualization of DNA Replication at Telomeres Using DNA Fiber Combing Combined with Telomere FISHHimabindu Gali, Emily Mason-Osann, Rachel Litman Flynn
Methods in Molecular Biology (Clifton, N.J.)|May 26, 2019
Resolving Roadblocks to Telomere ReplicationEmily Mason-Osann, Himabindu Gali, Rachel Litman Flynn
Plos One|March 25, 2015
Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell lineKevin Hollevoet, Emily Mason-Osann, Fabian Müller, et al.
Scientific Reports|June 27, 2015
Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro resultsEmily Mason-Osann, Kevin Hollevoet, Gerhard Niederfellner, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 7, 2015
Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in miceMichael L Manning, Emily Mason-Osann, Masanori Onda, et al.
Blood Cancer Discovery|January 17, 2024
Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid LeukemiaEmily Mason-Osann, Amy E Pomeroy, Adam C Palmer, et al.
Molecular Cancer Therapeutics|June 15, 2014
In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancerKevin Hollevoet, Emily Mason-Osann, Xiu-fen Liu, et al.
EMBO Reports|April 28, 2020
RAD54 promotes alternative lengthening of telomeres by mediating branch migrationEmily Mason-Osann, Katherine Terranova, Nicholas Lupo, et al.
Oncotarget|September 15, 2018
Identification of a novel gene fusion in ALT positive osteosarcomaEmily Mason-Osann, Anqi Dai, Jess Floro, et al.
Molecular Cell|August 27, 2019
SLX4IP Antagonizes Promiscuous BLM Activity during ALT MaintenanceStephanie Panier, Marija Maric, Graeme Hewitt, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Methods in Molecular Biology (Clifton, N.J.)|May 26, 2019
Direct Visualization of DNA Replication at Telomeres Using DNA Fiber Combing Combined with Telomere FISHHimabindu Gali, Emily Mason-Osann, Rachel Litman Flynn
Methods in Molecular Biology (Clifton, N.J.)|May 26, 2019
Resolving Roadblocks to Telomere ReplicationEmily Mason-Osann, Himabindu Gali, Rachel Litman Flynn
Plos One|March 25, 2015
Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell lineKevin Hollevoet, Emily Mason-Osann, Fabian Müller, et al.
Scientific Reports|June 27, 2015
Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro resultsEmily Mason-Osann, Kevin Hollevoet, Gerhard Niederfellner, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 7, 2015
Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in miceMichael L Manning, Emily Mason-Osann, Masanori Onda, et al.
Blood Cancer Discovery|January 17, 2024
Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid LeukemiaEmily Mason-Osann, Amy E Pomeroy, Adam C Palmer, et al.
Molecular Cancer Therapeutics|June 15, 2014
In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancerKevin Hollevoet, Emily Mason-Osann, Xiu-fen Liu, et al.
EMBO Reports|April 28, 2020
RAD54 promotes alternative lengthening of telomeres by mediating branch migrationEmily Mason-Osann, Katherine Terranova, Nicholas Lupo, et al.
Oncotarget|September 15, 2018
Identification of a novel gene fusion in ALT positive osteosarcomaEmily Mason-Osann, Anqi Dai, Jess Floro, et al.
Molecular Cell|August 27, 2019
SLX4IP Antagonizes Promiscuous BLM Activity during ALT MaintenanceStephanie Panier, Marija Maric, Graeme Hewitt, et al.
Pageof 1